Product NDC: | 62756-519 |
Proprietary Name: | CARBIDOPA AND LEVODOPA |
Non Proprietary Name: | CARBIDOPA AND LEVODOPA |
Active Ingredient(s): | 25; 250 mg/1; mg/1 & nbsp; CARBIDOPA AND LEVODOPA |
Administration Route(s): | ORAL |
Dosage Form(s): | TABLET |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 62756-519 |
Labeler Name: | Sun Pharmaceutical Industries Limited |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA078536 |
Marketing Category: | ANDA |
Start Marketing Date: | 20081028 |
Package NDC: | 62756-519-13 |
Package Description: | 500 TABLET in 1 BOTTLE (62756-519-13) |
NDC Code | 62756-519-13 |
Proprietary Name | CARBIDOPA AND LEVODOPA |
Package Description | 500 TABLET in 1 BOTTLE (62756-519-13) |
Product NDC | 62756-519 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | CARBIDOPA AND LEVODOPA |
Dosage Form Name | TABLET |
Route Name | ORAL |
Start Marketing Date | 20081028 |
Marketing Category Name | ANDA |
Labeler Name | Sun Pharmaceutical Industries Limited |
Substance Name | CARBIDOPA; LEVODOPA |
Strength Number | 25; 250 |
Strength Unit | mg/1; mg/1 |
Pharmaceutical Classes | Aromatic Amino Acid Decarboxylation Inhibitor [EPC],DOPA Decarboxylase Inhibitors [MoA],Aromatic Amino Acid Decarboxylation Inhibitor [EPC],DOPA Decarboxylase Inhibitors [MoA] |